Clinical Trials Logo

Ocular Toxoplasmosis clinical trials

View clinical trials related to Ocular Toxoplasmosis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04219176 Completed - Clinical trials for Ocular Toxoplasmosis

Spectral Optical Coherence Tomography Findings in Patients With Ocular Toxoplasmosis

Start date: January 23, 2002
Phase:
Study type: Observational

Ocular toxoplasmosis is the most common cause of infectious uveitis worldwide. The diagnosis of ocular toxoplasmosis is primarily clinical when it is a typical presentation .With an atypical presentation in the fundus, parasitological diagnosis is a decisive contribution, as well as multimodal imaging. We investigate on vitreal, retinal, and choroidal morphologic changes in active and scarred toxoplasmosis lesions using swept source optical coherence tomography.

NCT ID: NCT03948750 Completed - Clinical trials for Ocular Toxoplasmosis

Immunoblotting and Goldmann-Witmer Coefficient for Ocular Toxoplasmosis

COPILOT
Start date: January 1, 2010
Phase:
Study type: Observational

Ocular toxoplasmosis (OT) is a common cause of posterior uveitis worldwide. The diagnosis of OT is based on clinical findings, but in most cases, laboratory tests are required to confirm the etiology, especially when other diseases are suspected. The aim of this study was to evaluate which methods, between the Goldmann-Witmer coefficient (GWC) and immunoblotting (IB) with both IgG and IgA, in aqueous humour (AH) samples, can be the most sensitive to diagnose OT, in current practice, especially in the first three weeks.

NCT ID: NCT01449877 Completed - Clinical trials for Ocular Toxoplasmosis

Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis

ISROT
Start date: October 2011
Phase: Phase 3
Study type: Interventional

The investigators study aims to determine the effect of prophylactic therapy with Trimethoprim-sulfamethoxazole on the recurrences of toxoplasma retinochoroiditis gondii. This is a randomized, double-masked, in patients with eye condition of acute Toxoplasma gondii retinochoroiditis. Volunteers will be recruited with a previous diagnosis of chorioretinitis presumed Toxoplasma gondii, which show active lesions compatible with recurrence. After the acute phase of treatment of all patients [1 tablet Trimethoprim-sulfamethoxazole (800/160mg) 12/12h during 45 days], the same Stratified by gender) will be randomized in a 1:1 ratio between the group 1 - TMP-SMZ (prophylactic treatment with trimethoprim-sulfamethoxazole 1 tablet every other day for 311 days) or group 2 - placebo (consisting of a placebo pill containing no active ingredient of similar appearance to trimethoprim-sulfamethoxazole, 1 tablet every other day for 311 days). The primary outcomes are incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 12, 36, 48, 60, 72, 84, 96, 108, and 120 months. Patients will be followed during the ten years in uveitis clinic at intervals defined as follows: return weekly for 4 weeks, then monthly for 2 months, then each 3 months for 9 months, and finally annually for 10 years.